Question 3
What are the key differences between steroidal MRAs and nonsteroidal MRAs?
Daniel Ngui, BScPT, PT, MD, CCFP, FCFP
Question 4
For which patients should novel nonsteroidal MRAs be considered?
Normand Proulx, MD, FRCP(C)
Question 5
What data supports the use of novel nonsteroidal MRAs in patients already on an SGLT2 inhibitor?
Normand Proulx, MD, FRCP(C)
Question 6
When and how should potassium levels be monitored and managed in patients on MRAs?
Louise Moist, MD MSc CCPE FRCPC
No articles created yet
